English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [2303]
News [5290]
Articles [130]
Editorials [4]
Conferences [158]
elearning [13]
Choosing cancer medicines wisely in Africa
Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania
Choosing cancer medicines wisely in Africa ( Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania )
18 May 2023
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA...
Dr Susanne Gatz - Associate Clinical Professor in Paediatric Oncology, Cancer...
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours ( Dr Susanne Gatz - Associate Clinical Professor in Paediatric Oncology, Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK )
10 May 2023
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru
Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )
9 May 2023
Patient-derived iPSCs faithfully represent the genetic diversity and cellular...
Dr Eirini Papapetrou - Icahn School of Medicine at Mount Sinai, New York, USA
Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML ( Dr Eirini Papapetrou - Icahn School of Medicine at Mount Sinai, New York, USA )
28 Apr 2023
Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC
Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh...
Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC ( Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia )
27 Apr 2023
Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes...
Dr Joshua Choe - Columbia University, New York City, USA
Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death ( Dr Joshua Choe - Columbia University, New York City, USA )
27 Apr 2023
Breast and emerging indications for IORT
Dr David Martinez Perez - AUNA, Lima, Peru
Breast and emerging indications for IORT ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023
The advantages of IORT for early breast cancer treatment
Dr David Martinez Perez - AUNA, Lima, Peru
The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023
Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody...
Dr Attaya Suvannasankha - Indiana University Melvin and Bren Simon Cancer...
Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM ( Dr Attaya Suvannasankha - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
20 Apr 2023
ALLO-316 demonstrates encouraging anti-tumour activity for patients with...
Dr Samer Srour - The University of Texas MD Anderson Cancer Center, Houston, USA
ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC ( Dr Samer Srour - The University of Texas MD Anderson Cancer Center, Houston, USA )
20 Apr 2023
Atezo plus bev demonstrates efficacy in preventing recurrence in patients with...
Prof Pierce Chow - Duke-NUS Medical School, Singapore
Atezo plus bev demonstrates efficacy in preventing recurrence in patients with high-risk HCC ( Prof Pierce Chow - Duke-NUS Medical School, Singapore )
20 Apr 2023
IO-108 shows promising results in the treatment of advanced relapsed or...
Dr Matthew Taylor - Providence Cancer Institute, Portland, USA
IO-108 shows promising results in the treatment of advanced relapsed or refractory solid tumours ( Dr Matthew Taylor - Providence Cancer Institute, Portland, USA )
20 Apr 2023
<1...2223242526...192>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top